OmniAb, Inc. (NASDAQ:OABI) CEO Sells $135,467.64 in Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 41,811 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the sale, the chief executive officer now owns 3,749,639 shares of the company’s stock, valued at $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OmniAb Price Performance

Shares of OmniAb stock opened at $3.20 on Friday. The company has a 50-day moving average of $3.64 and a 200 day moving average of $4.05. OmniAb, Inc. has a 1 year low of $3.11 and a 1 year high of $6.55. The firm has a market cap of $451.90 million, a price-to-earnings ratio of -5.16 and a beta of -0.10.

Hedge Funds Weigh In On OmniAb

Several large investors have recently made changes to their positions in the business. SG Americas Securities LLC lifted its holdings in shares of OmniAb by 16.5% during the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after purchasing an additional 5,751 shares during the last quarter. Woodstock Corp lifted its holdings in shares of OmniAb by 1.2% during the fourth quarter. Woodstock Corp now owns 802,578 shares of the company’s stock valued at $2,841,000 after purchasing an additional 9,725 shares during the last quarter. Barclays PLC lifted its holdings in shares of OmniAb by 321.5% during the third quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after purchasing an additional 109,236 shares during the last quarter. State Street Corp lifted its holdings in shares of OmniAb by 1.7% during the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock valued at $8,594,000 after purchasing an additional 34,654 shares during the last quarter. Finally, Murchinson Ltd. purchased a new position in OmniAb in the 3rd quarter worth approximately $4,230,000. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have commented on OABI. Benchmark restated a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.